MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) is developing an AI-driven voice analysis platform designed to detect drug and alcohol intoxication in real time, addressing growing demand for faster, scalable and noninvasive impairment detection across workplace safety, healthcare and public safety markets. By leveraging speech as a diagnostic biomarker, the company is pursuing a differentiated approach to multisubstance intoxication detection within an evolving AI healthcare landscape that includes HeartFlow Inc. (NASDAQ: HTFL), Recursion Pharmaceuticals Inc. (NASDAQ: RXRX), Tempus AI Inc. (NASDAQ: TEM) and Butterfly Network Inc. (NYSE: BFLY).
As substance-use patterns evolve and the limitations of traditional testing methods become increasingly apparent, AI-enabled diagnostics are gaining momentum as a potential next-generation solution for real-time decision-making and risk management. MindBio is targeting large commercial opportunities spanning workplace compliance, telehealth and consumer health applications, positioning its voice-based platform within a broader transformation toward accessible, data-driven diagnostic technologies. The company's AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
The announcement comes as the real-time diagnostics market expands, driven by the need for rapid and noninvasive testing methods. Traditional methods such as breathalyzers and blood tests have limitations in terms of speed, cost, and invasiveness. AI-based approaches like MindBio's voice analysis platform could offer a more efficient alternative for employers, healthcare providers, and law enforcement agencies seeking to detect impairment quickly and accurately.
For more details, the full press release is available at https://ibn.fm/BZOb2. Additional information about MindBio Therapeutics and its latest news can be found at https://ibn.fm/MBQIF.
MindBio Therapeutics is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
